Roth cuts Recro Pharma to neutral with PT $7.50

Roth Capital Partners downgraded Recro Pharma (NASDAQ:REPH) to “neutral” with a price target of $7.50 after the company received a second complete response letter (CRL) from the FDA about its NDA for meloxicam, an intravenous treatment for moderate-to-severe pain. The stock closed at $9.72 on March 22.

Read More
Michelle Carr